Ipamorelin vs MK-677: Injectable Pentapeptide or Oral Small Molecule

On many supplement-marketing pages, MK-677 is filed under 'peptides'. That classification is wrong. A peptide, by definition, is a short chain of amino acids connected by peptide bonds. MK-677 is a spiropiperidine — its chemical structure is built from non-amino-acid heterocyclic chemistry. There are no peptide bonds in its structure.^[2]

Calling MK-677 a 'peptide' is shorthand for 'a molecule that mimics what some peptides do'. That distinction matters because peptide drugs and small-molecule drugs follow different pharmacokinetic rules. Peptides typically need parenteral routes (injection) because they would be degraded by gastrointestinal proteases if taken orally. MK-677's whole design point is that, as a non-peptide, it survives oral administration and is absorbed into systemic circulation.^[2][4]

If a product page describes MK-677 as 'a peptide for oral use', that is two contradictions: peptides are not typically orally bioavailable, and MK-677 is not a peptide in the first place. That is a content-quality flag, not a nuance.^[2]

The pharmacokinetic divergence between the two molecules is large enough to drive the entire user-experience difference. Ipamorelin, as a peptide given by subcutaneous injection, has a short plasma half-life in early discovery and clinical-pharmacology work — order of one to two hours — and its acute GH-release effect is similarly short-lived.^[1]

MK-677's published two-year clinical-pharmacology study in elderly adults reports sustained elevation of GH and IGF-1 markers for the duration of daily oral dosing — the molecule's pharmacokinetics support a 24-hour-plus elevation of the GH axis after a single daily dose. That is a fundamentally different exposure profile from ipamorelin's pulsed, short-acting peptide pharmacology.^[3][2]

Practically, that translates into very different research-protocol shapes. Ipamorelin studies usually involve repeated subcutaneous administration on a short cadence. MK-677 studies often run as single-daily-dose oral protocols over weeks to months. The molecules are not interchangeable as 'oral versus injectable versions of the same drug'.^[3][1]

The table below summarises what the published preclinical, clinical-pharmacology, and regulatory literature describes for each molecule. Read it as a research-context map, not a personal-use protocol.^[1][2][3]

| Attribute | Ipamorelin | MK-677 (Ibutamoren) | | --- | --- | --- | | Chemical class | Synthetic pentapeptide (5 amino acids), GHRP-6 derivative | Non-peptide spiropiperidine small molecule | | Is it a peptide? | Yes, by definition (five amino acids linked by peptide bonds) | No — small-molecule GHRP mimetic, not a peptide | | Receptor target | GHSR-1a (ghrelin / growth-hormone-secretagogue receptor) | GHSR-1a (ghrelin / growth-hormone-secretagogue receptor) | | Route of administration | Subcutaneous injection | Oral (designed for oral bioavailability) | | Reported pharmacokinetics | Short plasma half-life — order of ~1-2 hours in early discovery work | Sustained 24-hour-plus elevation of GH/IGF-1 markers on once-daily oral dosing in long-duration studies | | Selectivity profile | Described as selective for GH release with low effect on cortisol or prolactin in original discovery work | Long-term studies report increases in GH/IGF-1; published data on cortisol effects exists in elderly cohorts | | Typical research framing | GHRP-class pharmacology, GH-axis acute stimulation | Long-duration GH/IGF-1 elevation, body-composition and elderly-population research | | EMA / EU regulatory status | No EMA EPAR; not an authorised medicine | No EMA EPAR; not an authorised medicine | | WADA prohibited-list status | Prohibited (S2 - peptide hormones, growth factors, related substances and mimetics) | Prohibited (S2 - peptide hormones, growth factors, related substances and mimetics) | | Common buyer question | 'Why injectable if MK-677 is oral?' | 'Why is the oral one stronger over 24 hours?' | | Honest answer | Because it is a peptide, and peptides are not orally stable. | Because it was specifically designed as an orally bioavailable mimetic. |^{[1][2][3][4][5][6]}

Use the table to map the research stories. It is not a buying chart, a dosing schedule, or a recommendation for any individual.

Both ipamorelin and MK-677 are listed under the WADA Prohibited List's S2 category (peptide hormones, growth factors, related substances and mimetics). 'Related substances and mimetics' is the catch-all phrase that brings non-peptide GH secretagogues like MK-677 into the same anti-doping bucket as peptide GHRPs like ipamorelin. Both are prohibited at all times in competitive sport — no in-competition / out-of-competition distinction.^[5]

Neither molecule has an EMA EPAR as a marketed medicine. In Europe, the EMA-authorised pathway for diagnosed adult or paediatric growth-hormone deficiency is recombinant human growth hormone (somatropin), prescribed by an endocrinologist after diagnostic workup. Ipamorelin and MK-677 sit outside that consumer-medicine pathway entirely.^[6][7]

The combination is worth holding in mind: both molecules have meaningful preclinical and clinical-pharmacology footprints, but neither has cleared the threshold of EMA authorisation, and both are explicitly prohibited in sport. That is the honest regulatory frame for any 'ipamorelin or ibutamoren' decision.^[5][6]